Livongo Health last week filed for an initial public offering worth $100 million for the digital health platform it developed to treat chronic diseases.
The Mountain View, Calif.-based company’s initial focus on diabetes involves a smart, cellular-connected glucose meter, automatically-delivered testing materials, real-time coaching and full-time monitoring. The system personalizes messages based on each glucose reading that the company calls a “health nudge.”
“Today, we have created a unified platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications to help our members live better and healthier lives,” Livongo said in its registration filing.
Rumors swirled in March that Livongo was prepping an IPO worth a full order of magnitude more, slated for the third quarter.
In September 2018 Livongo integrated continuous glucose data from the Abbott (NYSE:ABT) FreeStyle Libre Pro system into its diabetes system.
